Schmidinger M - Search Results

1

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.

Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, Motzer RJ, Atkins MB, Haanen J, Mariani M, Wang J, Hariharan S, Larkin J. Rini BI, et al. Among authors: schmidinger m. J Clin Oncol. 2022 Jun 10;40(17):1929-1938. doi: 10.1200/JCO.21.01806. Epub 2022 Mar 3. J Clin Oncol. 2022. PMID: 35239416 Free PMC article.

2

Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group.

Schmidinger M, Steger GG, Wenzel C, Locker GJ, Brodowicz T, Budinsky AC, Wiltschke C, Kramer G, Marberger M, Zielinski CC. Schmidinger M, et al. Cancer Immunol Immunother. 2000 Sep;49(7):395-400. doi: 10.1007/s002620000128. Cancer Immunol Immunother. 2000. PMID: 10999466 Free PMC article. Clinical Trial.

3

Aldesleukin in advanced renal cell carcinoma.

Schmidinger M, Hejna M, Zielinski CC. Schmidinger M, et al. Expert Rev Anticancer Ther. 2004 Dec;4(6):957-80. doi: 10.1586/14737140.4.6.957. Expert Rev Anticancer Ther. 2004. PMID: 15606326 Review.

4

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Schmidinger M, et al. Among authors: schmidinger h. J Clin Oncol. 2008 Nov 10;26(32):5204-12. doi: 10.1200/JCO.2007.15.6331. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838713

5

Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.

Schmidinger M, Zielinski CC. Schmidinger M, et al. Cancer Treat Rev. 2009 May;35(3):289-96. doi: 10.1016/j.ctrv.2009.01.004. Epub 2009 Feb 15. Cancer Treat Rev. 2009. PMID: 19232474 Review.

6

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Schmidinger M, Bellmunt J. Schmidinger M, et al. Cancer Treat Rev. 2010 Aug;36(5):416-24. doi: 10.1016/j.ctrv.2010.01.003. Epub 2010 Feb 16. Cancer Treat Rev. 2010. PMID: 20163917 Review.

7

Defining risk status in the first-line treatment of metastatic renal cell carcinoma.

Schmidinger M, Zielinski CC. Schmidinger M, et al. J Cancer Res Clin Oncol. 2010 Jul;136(7):961-8. doi: 10.1007/s00432-010-0901-0. Epub 2010 May 8. J Cancer Res Clin Oncol. 2010. PMID: 20454802 Review.

8

Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.

Schmidinger M, Szczylik C, Sternberg CN, Kania M, Kelly CS, Decker R, Hamid O, Faelker T, Escudier B. Schmidinger M, et al. Am J Clin Oncol. 2012 Oct;35(5):493-7. doi: 10.1097/COC.0b013e31821cfc41. Am J Clin Oncol. 2012. PMID: 21654314 Clinical Trial.

9

Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma.

Schmidinger M, Bergler-Klein J. Schmidinger M, et al. Int J Urol. 2012 Sep;19(9):796-804. doi: 10.1111/j.1442-2042.2012.03033.x. Epub 2012 May 14. Int J Urol. 2012. PMID: 22583077 Review.

10

Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.

Ahlbrecht J, Dickmann B, Ay C, Dunkler D, Thaler J, Schmidinger M, Quehenberger P, Haitel A, Zielinski C, Pabinger I. Ahlbrecht J, et al. Among authors: schmidinger m. J Clin Oncol. 2012 Nov 1;30(31):3870-5. doi: 10.1200/JCO.2011.40.1810. Epub 2012 Sep 24. J Clin Oncol. 2012. PMID: 23008313

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters